MedTrace Logo

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

NCT02564744 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-06-12

Study results available
· View outcomes & findings →

Summary

The primary purpose of the study was to determine the safety and tolerability, anti-tumor activity of the proposed Debio 1562 dose regimens in combination with rituximab.

Conditions

  • Diffuse Large B-Cell Lymphoma
  • B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG

Debio 1562

Administered as IV Infusion.

DRUG

Rituximab

Administered as IV Infusion.

Sponsors & Collaborators

  • Debiopharm International SA

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-05
Primary Completion
2021-01-13
Completion
2021-06-25
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Bulgaria
  • Czechia
  • Hungary
  • Italy
  • Poland
  • Switzerland
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02564744 on ClinicalTrials.gov